子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | ANTI-MUTATED KRAS T CELL RECEPTORS | US15528813 | 2015-11-24 | US20170304421A1 | 2017-10-26 | Qiong J. WANG; Zhiya YU; James C. YANG |
| Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for an HLA-A11-restricted epitope of mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) (KRAS7-16), Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS), or Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS). Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal. | ||||||
| 2 | USE OF PHOSPHOLIPID SCRAMBLASE INHIBITORS FOR MODULATING INFLAMMATORY IMMUNE RESPONSES | US15849069 | 2017-12-20 | US20180171305A1 | 2018-06-21 | Axel Nimmerjahn; Charles L. Clark |
| The finding that phosphatidylserine (PtdSer) exposure on the outer leaflet of virally transduced cells triggers their engulfment by resident immune cells is described. It is demonstrated that inhibition of phospholipid scramblase 1 (PLSCR1) activity prevents PtdSer externalization and enables prolonged protection of vector-transduced cells from phagocytosis. Methods of inhibiting a virus vector-induced inflammatory response in tissue, methods of prolonging virus vector encoded transgene expression, and methods of modulating an inflammatory response in tissue of a subject, by administering an inhibitor of PLSCR1 are described. | ||||||
| 3 | High efficiency FLP site-specific recombination in mammalian cells using an optimized FLP gene | US12307418 | 2007-06-21 | US09206397B2 | 2015-12-08 | Christopher Raymond; Philippe Soriano |
| The present invention provides an optimized FLP site-specific recombinase coding sequence and methods for its use. This genetically engineered FLP gene displays a marked increase in recombination efficiency compared to the native FLP gene and is therefore useful in a wide array of molecular applications. | ||||||
| 4 | 抗突然変異ＫＲＡＳ Ｔ細胞受容体 | JP2017527874 | 2015-11-24 | JP2017536825A | 2017-12-14 | ジェイ． ワン、チョン; ユ、ジヤ; シー． ヤン、ジェームズ |
| 突然変異カーステン・ラット肉腫ウイルスがん遺伝子ホモログ(KRAS)(KRAS7−16)、神経芽細胞腫RASウイルス(V−Ras)がん遺伝子ホモログ(NRAS)、又はハーベイラット肉腫ウイルスがん遺伝子ホモログ(HRAS)のHLA−A11拘束性エピトープに対し抗原特異性を有する、単離又は精製されたT細胞受容体(TCR)が開示される。関連するポリペプチド及びタンパク質、並びに関連する核酸、組換え発現ベクター、宿主細胞、細胞集団及び医薬組成物も提供される。哺乳動物におけるがんの存在を検出する方法、及び哺乳動物におけるがんを治療又は予防する方法も開示される。【選択図】なし | ||||||
| 5 | CRYSTAL STRUCTURE OF A TYPE IB P-TYPE ATPASE | EP12706446.7 | 2012-01-20 | EP2665813A2 | 2013-11-27 | NISSEN, Poul; GOURDON, Pontus; LIU, Xiangyu; PEDERSEN, Bjørn Panyella; MATTLE, Daniel |
| The present invention relates to crystals of a type IB P-type ATPase having the space group P1 and methods for purification and growing said crystals. The invention also presents methods for identifying an inhibitor of a type IB P-type ATPase for example by determining binding interactions between an inhibitor and a set of binding interaction sites in said type IB P-type ATPase. | ||||||
| 6 | MEANS AND METHODS FOR HYPER-PRODUCTION OF AUTHENTIC HUMAN BASIC FIBROBLAST GROWTH FACTOR IN ESCHERICHIA COLI | US15409137 | 2017-01-18 | US20170183704A1 | 2017-06-29 | Wai Yeung KWONG; Wan Keung Raymond WONG |
| The present invention is concerned with a method of production of authentic human epidermal growth factor (EGF) and hyper-production of authentic basic fibroblast growth factor (bFGF) without any modification at either C- or N-terminal of the bFGF. | ||||||
| 7 | HIGH EFFICIENCY FLP SITE-SPECIFIC RECOMBINATION IN MAMMALIAN CELLS USING AN OPTIMIZED FLP GENE | US14959247 | 2015-12-04 | US20160083699A1 | 2016-03-24 | Christopher Raymond; Philippe Soriano |
| The present invention provides an optimized FLP site-specific recombinase coding sequence and methods for its use. This genetically engineered FLP gene displays a marked increase in recombination efficiency compared to the native FLP gene and is therefore useful in a wide array of molecular applications. | ||||||
| 8 | CRYSTAL STRUCTURE OF A TYPE IB P-TYPE ATPase | US13980626 | 2012-01-20 | US20150045284A1 | 2015-02-12 | Poul Nissen; Pontus Gourdon; Xiang Liu; Bjorn Panyella Pedersen; Daniel Mattle |
| The present invention relates to crystals of a type IB P-type ATPase having the space group P1 and methods for purification and growing said crystals. The invention also presents methods for identifying an inhibitor of a type IB P-type ATPase for example by determining binding interactions between an inhibitor and a set of binding interaction sites in said type IB P-type ATPase. | ||||||
| 9 | HIGH EFFICIENCY FLP SITE-SPECIFIC RECOMBINATION IN MAMMALIAN CELLS USING AN OPTIMIZED FLP GENE | US12307418 | 2007-06-21 | US20100050279A1 | 2010-02-25 | Christopher Raymond; Philippe Soriano |
| The present invention provides an optimized FLP site-specific recombinase coding sequence and methods for its use. This genetically engineered FLP gene displays a marked increase in recombination efficiency compared to the native FLP gene and is therefore useful in a wide array of molecular applications. | ||||||
| 10 | 항-돌연변이 KRAS T 세포 수용체 | KR1020177017289 | 2015-11-24 | KR1020170099905A | 2017-09-01 | 왕키옹제이; 유지야; 양제임스씨 |
| 돌연변이된키르스텐래트육종바이러스암유전자동족체(KRAS)(KRAS), 신경모세포종 RAS 바이러스(V-Ras) 암유전자동족체(NRAS) 또는하비래트육종바이러스암유전자동족체(HRAS)의 HLA-A11-제한된에피토프에대한항원특이성을갖는, 단리되거나정제된 T 세포수용체(TCR)가개시되어있다. 관련된폴리펩티드및 단백질뿐 아니라, 관련된핵산, 재조합발현벡터, 숙주세포, 세포집단및 약학조성물도또한제공된다. 또한, 포유동물에서암의존재를검출하는방법및 포유동물에서암을치료하거나예방하는방법도개시되어있다. | ||||||
| 11 | HIGH EFFICIENCY FLP SITE-SPECIFIC RECOMBINATION IN MAMMALIAN CELLS USING AN OPTIMIZED FLP GENE | PCT/US2007014482 | 2007-06-21 | WO2008008160A3 | 2008-11-27 | RAYMOND CHRISTOPHER; SORIANO PHILIPPE |
| The present invention provides an optimized FLP site-specific recombinase coding sequence and methods for its use. This genetically engineered FLP gene displays a marked increase in recombination efficiency compared to the native FLP gene and is therefore useful in a wide array of molecular applications. | ||||||
| 12 | CRYSTAL STRUCTURE OF A TYPE IB P-TYPE ATPASE | PCT/DK2012050026 | 2012-01-20 | WO2012097826A3 | 2013-03-21 | NISSEN POUL; GOURDON PONTUS; LIU XIANGYU; PEDERSEN BJOERN PANYELLA; MATTLE DANIEL |
| The present invention relates to crystals of a type IB P-type ATPase having the space group P1 and methods for purification and growing said crystals. The invention also presents methods for identifying an inhibitor of a type IB P-type ATPase for example by determining binding interactions between an inhibitor and a set of binding interaction sites in said type IB P-type ATPase. | ||||||
QQ群二维码
意见反馈
意见反馈